Intermediate stages of the implementation of the Moscow program "Histoscanning of the prostate gland"

Introduction. Prostate cancer (prostate cancer) ranks second in the list of all oncological diseases in men in the world. Thus taking the fifth place among the causes of death of the male population. Differences in the frequency of cases worldwide are due to differences in the use of diagnostic tests. The widespread introduction into clinical practice of screening, including the determination of the level of prostate-specific antigen (PSA), finger rectal examination (PRI) and transrectal or transabdominal ultrasound examination, contributed to an even greater increase in the number of newly detected cases of prostate cancer at an early stage.  

Materials and methods. In 2019, we initiated and launched a prospective multicenter study in 13 medical and preventive institutions.  

Results and discussion. As part of the ongoing study, data from 2,570 patients were analyzed, who simultaneously underwent both a standard 12-point biopsy and a targeted biopsy under the control of a GP. Technological breakthrough and progressive development of medical technologies have led to the modernization of modern methods of visualization of pelvic organs, allowing the introduction of a new, alternative and minimally invasive method of cancer diagnosis – prostate histoscanning. The published results of clinical studies have shown that histoscanning of the prostate gland has great potential in the diagnosis of cancer, as it helps both in choosing a treatment method and in planning the course of further surgery, as well as in the follow-up of patients.  

Conclusion. The results of a prospective study collected at the time of writing confirm the high efficiency and safety of the prostate biopsy method using histoscanning.

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2020, № 68(6), pp. 394–424. https://doi.org/https://doi.org/10.25557/2310-0435.2018.01.4-10

2. Vasilyev A.O., Shiryaev A.A., Govorov A.V., Demin A.A., Okishev A.V., Sidorenkov A.V., Pushkar D.Yu. Biomarkers in early prostate cancer diagnosis. Pathogenesis, 2018, № 16(1), pp. 4–11. (In Russian) https://doi.org/10.25557/2310-0435.2018.01.4-10

3. Smeenge M., de la Rosette J.J., Wijkstra H. Current status of transrec­tal ultrasound techniques in prostate cancer. Curr Opin Urol, 2012, № 22(4), pp. 297–302. https://doi.org/10.1097/mou.0b013e3283548154

4. Loeb S., Vellekoop A., Ahmed H.U., Catto J., Emberton M. et al. Sys­tematic review of complications of prostate biopsy. Eur Urol, 2013, № 64(6), pp. 876–892. https://doi.org/10.1016/j.eururo.2013.05.049

5. Braeckman J., Autier P., Soviany C., Nir R., Nir D., Michielsen D. et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int, 2008, № 102(11), pp. 1560–1565. https://doi.org/10.1111/j.1464-410x.2008.07878.x

6. Braeckman J., Autier P., Garbar C., Marichal M.P., Soviany C., Nir R. et al. Computer-aided ultrasonography (HistoScanning): a novel technolo­gy for locating and characterizing prostate cancer. BJU Int, 2008, № 101(3), pp. 293–298. https://doi.org/10.1111/j.1464-410x.2007.07232.x

7. Macek P., Barret E., Sanchez-Salas R., Galiano M., Rozet F., Ahallal Y. et al. Prostate histoscanning in clinically localized biopsy proven prostate cancer – an accuracy study. J Endourol, 2014, 28(3), pp. 371–376. https://doi.org/10.1089/end.2013.0419

8. Mottet. N. EAU Guidelines on Prostate Cancer European Associa­tion of Urology, 2020, № 7, рр. 243–262.

9. Okishev A.V., Govorov A.V., Vasilyev A.O., Bormotin A.V., Mytali­bova G.Yu., Pushkar D.Yu. The ability of visual reproduction as one of the key factors in the effectiveness of cognitive fusion biopsy MRI in the diag­nosis of prostate cancer. Materials of the XIII International Congress of the Russian Society of Oncourology, 2018, pp. 42–43. (In Russian).

10. Govorov A.V., Vasilyev A.V., Sadchenko A.V., Prilepskaya E.A., Kovilina M.V., Pushkar D.Yu. The role of prostate histoscanning in de­tecting prostate cancer. Consilium Medicum, 2018, № 17(7), pp. 8–11. (In Russian).

11. Govorov A.V., Vasilyev A.O., Kovilina M.V., Prilepskaya E.A., Moi­seenko T.A., Pushkar D.Yu. Prostate histoscanning. Correlation of results with data of pathomorphological examination after radical prostatectomy. Eur. Oncological J, 2014, № 3(03), pp. 687. (In Russian).

12. Simmons L.A., Autier P., Zatura F., Braeckman J., Peltier A., Romic I. et al. Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning™. BJU Int, 2012, № 110(1), pp. 28–35. https://doi.org/10.1111/j.1464-410x.2011.10734.x

13. Rosenkrantz A.B., Deng F.M., Kim S., Lim R.P., Hindman N., Mussi T.C. et al. Prostate cancer: multiparametric MRI for index lesion lo­calization–a multiple-reader study. Am J Roentgenol, 2012, № 199(4), pp. 830–837. https://doi.org/10.2214/ajr.11.8446

14. De Coninck V., Braeckman J., Michielsen D. Prostate histoscan­ning: a screening tool for prostate cancer? Int J Urol, 2013, № 20(12), pp. 1184–1190. https://doi.org/10.1111/iju.12148

15. Javed S., Chadwick. E, Edwards A.A., Beveridge S., Laing R., Bott S. et al. Does prostate HistoScanning™ play a role in detecting pros­tate cancer in routine clinical practice? Results from three independent studies. BJU Int, 2013, № 114(4), pp. 541–548. https://doi.org/10.1111/bju.12568